Treatment of hepatitis C with new fixed dose combinations

@article{Soriano2017TreatmentOH,
  title={Treatment of hepatitis C with new fixed dose combinations},
  author={Vincent Soriano and Jos{\'e} Vicente Fern{\'a}ndez-Montero and Carmen de Mendoza and Laura Ben{\'i}tez-Guti{\'e}rrez and Jos{\'e} Ma Pe{\~n}a and Ana Arias and Pablo Barreiro},
  journal={Expert Opinion on Pharmacotherapy},
  year={2017},
  volume={18},
  pages={1235 - 1242}
}
ABSTRACT Introduction: The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%. However, a subset of patients remains at higher risk for treatment failure, including those infected with: i) genotype 3 and cirrhosis; ii) resistance-associated substitutions (RAS) occurring either as natural polymorphisms or selected after prior DAA failure; and iii) poor drug adherence associated with social disabilities… Expand
NS5B polymerase inhibitors in phase II clinical trials for HCV infection
TLDR
This review outlines the main clinical data concerning novel NS5B polymerase inhibitors currently in pipeline, focusing on the ones that have completed a phase 2 trial. Expand
Is Ribavirin Teratogenic in Humans? No Evidence So Far
TLDR
An interim analysis is made of the major findings collected at the Ribavirin Pregnancy Registry, a large database established in 2003 in USA in response to a Food and Drug Administration post-marketing request to collect information from pregnant women exposed to RBV. Expand
Benefits of hepatitis C cure with antivirals: why test and treat?
TLDR
There is no doubt that the individual success of direct-acting antivirals is largely contributing to halt HCV transmission globally, in the absence of an effective HCV prophylactic vaccine. Expand
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
TLDR
Overall, most adverse events (AEs) were mild‐to‐moderate in severity with serious AEs and AEs leading to G/P discontinuation occurring at similarly low rates in both patient populations. Expand
Need to Face Liver Cirrhosis after HCV Cure with Antivirals
TLDR
The first proof-of-concept of significant improvement of hepatic fibrosis in a small subset of patients with compensated cirrhosis due to chronic hepatitis C that received escalating doses of PRI724, an experimental CBP-β-catenin small molecule inhibitor is reported. Expand
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
TLDR
8-week G/P treatment is safe and efficacious in DAA-naive patients without cirrhosis and with HCV GT1 or GT2 infection, demonstrating high SVR12 rates regardless of baseline patient and disease characteristics. Expand
Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China
TLDR
Subtype-specific distribution patterns of NS5A RASs were observed, indicating circulation of both locally and nationally epidemic strains and patients with higher HCV complexity tend to have a greater chance of Y93H presence, while GT3b patients are naturally resistant to currentNS5A inhibitors and their treatment may pose a challenge to real-world DAA application. Expand
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients
TLDR
The recent multi-targeted regimen of SOF plus OBV/PTV/r + RBV was well tolerated and achieved excellent SVR rates among retreatment-experienced Egyptian patients with prior DAA treatments failure, thus providing an alternative regimen for the retreatment of difficult-to-cure HCV GT4 patients. Expand
Current and future challenges in HCV: insights from an Italian experts panel
TLDR
A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Expand
Prevention of liver cancer with new curative hepatitis C antivirals: Real‐world challenges
TLDR
The advent of new HCV drugs known as direct-acting antivirals (DAAs), which provide unprecedented and very high curative rates with short courses (8-12 weeks) of oral therapy, has transformed chronic hepatitis C into a curable condition and form the basis for evaluating the impact of DAA therapy in the coming years. Expand
...
1
2
...

References

SHOWING 1-10 OF 66 REFERENCES
Prevention and management of treatment failure to new oral hepatitis C drugs
TLDR
The management of HCV treatment failure and the impact of RAVs on re-treatment strategies are discussed and it is unclear when and how to re-treat hepatitis C in patients with prior DAA failure. Expand
Hepatitis C virus resistance to the new direct-acting antivirals
TLDR
Although DAA failures generally occur in less than 10% of treated chronic hepatitis C patients, selection of drug resistance is the rule in most cases and first-line therapeutic strategies should be optimized to efficiently prevent DAA failure due to baseline HCV resistance. Expand
Management of direct-acting antiviral agent failures.
TLDR
The optimal treatment for patients who fail an NS5A inhibitor and those with multidrug-resistant variants remains to be defined, and research efforts should continue to focus on treatment for these patients. Expand
Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions
TLDR
Current and emergent DAA regimens for HCV-GT3 treatment are discussed, and disruption of HCV entry by targeting required host cellular receptors shows potential in minimizing HCV resistance and broadening therapeutic options for certain subpopulations of GT3 patients. Expand
Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries
TLDR
The Australian Government has allocated AUS$1 billion to the Pharmaceutical Benefits Scheme to fund HCV DAA therapies for the next 5 years, with no restrictions based on liver disease stage, and high drug pricing for interferon-free DAA regimens has limited broad implementation in the vast majority of settings. Expand
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
TLDR
Geno- and phenotypic resistance testing as well as clinical data on the importance of RAVs for conventional triple therapies with sofosbuvir, simeprevir, and daclatasvir and available interferon-free DAA combinations are discussed. Expand
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
TLDR
First-line treatment strategies should be optimized to efficiently prevent treatment failure due to HCV resistance, as viral variants resistant to NS5A inhibitors at baseline is associated with lower rates of virological cure in certain groups of patients. Expand
Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
  • C. Macbrayne, J. Kiser
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2016
TLDR
The clinical pharmacology and drug interaction potential of the DAAs, the interaction data with DAAs and antiretroviral agents, and the knowledge gaps in the pharmacologic aspects of treating HCV in individuals with HIV coinfection are described. Expand
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
TLDR
In a phase 2 open-label trial, 8 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 to be safe and effective in treatment-naive patients; 12 weeks was safe andeffective in patients previously treated with DAAs. Expand
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
TLDR
The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA‐containing therapy; RBV coadministration did not improve efficacy. Expand
...
1
2
3
4
5
...